All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
COMMODORE trial: Long-term follow up of gilteritinib vs salvage chemotherapy in R/R FLT3-mutated AML
Gilteritinib is an FLT3 inhibitor approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with relapsed/refractory (R/R) FLT3-mutated (FLT3m) acute myeloid leukemia (AML). The primary analysis of the phase III COMMODORE trial (NCT03182244) demonstrated significant improvements in overall survival (OS) and event-free survival (EFS) rates with gilteritinib vs salvage chemotherapy in predominantly Asian patients with R/R FLT3m AML. However, long-term data on the efficacy and safety of gilteritinib treatment in Asian populations with FLT3m AML are limited. During the European Hematology Association (EHA) 2025 Congress, June 12–15, 2025, Milan, IT, Jianxiang Wang presented long-term follow-up data from the COMMODORE trial in patients treated with gilteritinib (n = 137) vs salvage chemotherapy (n = 139). The primary endpoint was OS; key secondary endpoints were EFS and complete remission rate. The median follow-up was 34.6 months.
|
Key learnings |
Gilteritinib showed long-term OS and EFS benefit compared with salvage chemotherapy, with a 39% reduction in the risk of death (HR, 0.61; p = 0.0015) and a 41% reduction in the risk of an event (HR, 0.589; p = 0.00005), respectively. |
CR (20.4% vs 11.5%) and CRc (53.3% vs 22.3%) rates were higher with gilteritinib than with salvage chemotherapy, respectively. The ORR was also higher with gilteritinib compared with salvage chemotherapy (67.9% vs 27.3%). |
A higher proportion of patients underwent HSCT with gilteritinib than with salvage chemotherapy (22.6% vs 7.9%), with 80.6% of patients treated with gilteritinib receiving on-study HSCT. |
Gilteritinib was well tolerated and continued to demonstrate clinical benefit vs salvage chemotherapy for up to 3 years in patients with R/R FLT3m AML. The findings validate the long-term efficacy and safety of gilteritinib. |
AML, acute myeloid leukemia; CRc, composite CR; CR, complete remission; EFS, event-free survival; EHA, European Hematology Association; FLT3m, FLT3-mutated; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; ORR, overall response rate; OS, overall survival; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When treating a patient newly diagnosed with IDH1-mutated AML who is ineligible for intensive chemotherapy, which initial treatment approach would you most likely consider?
